testosterone
Trade name: delatestryl
Approved
Dec 24, 1953
Testosterone is a steroid sex hormone found in both men and women. In men, testosterone is produced primarily by the Leydig (interstitial) cells of the testes when stimulated by luteinizing hormone (LH). It functions to stimulate spermatogenesis, promote physical and functional maturation of spermatozoa, maintain accessory organs of the male reproductive tract, support development of secondary sexual characteristics, stimulate growth and metabolism throughout the body and influence brain development by stimulating sexual behaviors and sexual drive. In women, testosterone is produced by the ovaries (25%), adrenals (25%) and via peripheral conversion from androstenedione (50%). Testerone in women functions to maintain libido and general wellbeing. Testosterone exerts a negative feedback mechanism on pituitary release of LH and follicle-stimulating hormone (FSH). Testosterone may be further converted to dihydrotestosterone or estradiol depending on the tissue. The effects of testosterone in humans and other vertebrates occur by way of two main mechanisms: by activation of the androgen receptor (directly or as DHT), and by conversion to estradiol and activation of certain estrogen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects. Testosterone is used as hormone replacement or substitution of diminished or absent endogenous testosterone. Use in males: For management of congenital or acquired hypogonadism, hypogonadism associated with HIV infection, and male climacteric (andopause). Use in females: For palliative treatment of androgen-responsive, advanced, inoperable, metastatis (skeletal) carcinoma of the breast in women who are 1-5 years postmenopausal; testosterone esters may be used in combination with estrogens in the management of moderate to severe vasomotor symptoms associated with menopause in women who do not respond to adequately to estrogen therapy alone. — NCATS
Clinical trial activity
453 trials · 332 clinical orgs · 58 marketing orgs
Earliest trial started Oct 1, 1992 (NCT00004771)
Timeline
1950s
- Dec 24, 1953
Endo Pharmaceuticals — Earliest FDA Approval
- Dec 24, 1953
Endo Pharmaceuticals — NDA Secondary Org
- Dec 24, 1953
Endo Pharmaceuticals — NDA Organization
1970s
- Jul 13, 1972
Auxillium — Marketing Organization
- Dec 3, 1973
Belmar Pharmacy — Marketing Organization
- Jun 23, 1978
Watson Pharmaceuticals — Marketing Organization
- Jul 25, 1979
Pharmacia & Upjohn — Marketing Organization
- Jul 25, 1979
Pfizer — Marketing Organization
1980s
- Jun 13, 1980
Pharmacia & Upjohn — NDA Secondary Org
- Jun 29, 1982
Savage Labs — Marketing Organization
1990s
2000s
- Jan 1, 2000
Earliest Phase 1 Sponsor(trial)
- Feb 28, 2000
AbbVie — NDA Secondary Org
- Feb 28, 2000
Besins Healthcare — Marketing Organization
- Feb 28, 2000
Besins Healthcare — NDA Secondary Org
- Oct 31, 2002
Auxillium — NDA Secondary Org
- Jan 31, 2005
Paddock Laboratories — Marketing Organization
- Jan 31, 2005
Padagis Us — Marketing Organization
- Jan 27, 2006
Actavis — Marketing Organization
- Jun 14, 2006
Nexus Pharmaceuticals — Marketing Organization
- Aug 10, 2006
Sandoz — Marketing Organization
- Aug 10, 2006
Novartis — Marketing Organization
- Dec 11, 2006
Mylan — Marketing Organization
- Dec 11, 2006
Rising Pharmaceuticals — Marketing Organization
- May 23, 2007
Par Pharmaceuticals — Marketing Organization
- May 23, 2007
Strides Pharma Science — Marketing Organization
2010s
- Jul 15, 2010
Hikma — Marketing Organization
- Jul 15, 2010
West-Ward Pharmaceutical — Marketing Organization
- Nov 23, 2010
Eli Lilly — NDA Secondary Org
- Dec 29, 2010
Bristol-Myers Squibb — NDA Secondary Org
- Feb 14, 2012
Ani Pharmaceuticals — NDA Secondary Org
- Jan 31, 2013
Perrigo — NDA Secondary Org
- Jun 3, 2013
Sun Pharmaceuticals — Marketing Organization
- Mar 5, 2014
Endo Pharmaceuticals — Marketing Organization
- May 28, 2014
AYTU BioScience — NDA Secondary Org
- May 28, 2014
Acerus Pharmaceuticals Corporation — Marketing Organization
- May 28, 2014
Bausch Health Companies — NDA Secondary Org
- Jun 4, 2014
Upsher-Smith Laboratories — NDA Secondary Org
- Aug 5, 2015
Allergan PLC (2015) — Marketing Organization
- Jun 16, 2017
Lutipold — Marketing Organization
- Jun 16, 2017
Sankyo — Marketing Organization
- Jun 16, 2017
Daiichi Sankyo — Marketing Organization
- Jul 12, 2017
Perrigo — Marketing Organization
- Oct 23, 2017
Lupin — Marketing Organization
- Jan 29, 2018
Cipla — Marketing Organization
- Sep 28, 2018
Antares Pharma Inc. — NDA Secondary Org
- Mar 27, 2019
Clarus Therapeutics, Inc. — NDA Secondary Org
- Mar 27, 2019
Clarus Therapeutics, Inc. — Marketing Organization
- Mar 27, 2019
Tolmar Inc. — Marketing Organization
- Mar 27, 2019
Tolmar Inc. — NDA Secondary Org
- Apr 10, 2019
Amneal Pharmaceuticals — Marketing Organization
- Apr 10, 2019
Dr. Reddy's Laboratories — Marketing Organization
- Apr 24, 2019
Wilshire Pharmaceuticals — Marketing Organization
- Sep 23, 2019
TWi Biotechnology, Inc. — Marketing Organization
2020s
- Apr 16, 2020
Exeltis — Marketing Organization
- Nov 25, 2020
Apotex — Marketing Organization
- Dec 8, 2020
Lipocine Inc. — Marketing Organization
- Jan 11, 2021
Dash Pharms — Marketing Organization
- Mar 3, 2021
Alembic — Marketing Organization
- Nov 9, 2021
Encube Ethicals Pvt. Ltd. — Marketing Organization
- Mar 28, 2022
Verity Pharmaceuticals — Marketing Organization
- Jun 2, 2022
Azurity — Marketing Organization
- Jun 2, 2022
Slayback Pharma Llc — Marketing Organization
- Jun 2, 2022
Slayback Pharma Llc — NDA Secondary Org
- Jul 27, 2022
MARIUS PHARMS LLC — Marketing Organization
- Jul 27, 2022
MARIUS PHARMS LLC — NDA Secondary Org
- Oct 20, 2023
Eugia Pharma — Marketing Organization
Indications
Studied for
- Abnormalities, Drug-Induced · Phase 4
- Acute Pain · Early Phase 1
- Aging · Phase 4
- Alzheimer Disease · Phase 3
- Amyotrophic Lateral Sclerosis · Phase 2
- Analgesics, Opioid · Phase 2
- Androgens · Phase 3
- Andropause · Phase 3
- Anemia, Sickle Cell · Early Phase 1
- Angina Pectoris · Phase 4
- Anorexia Nervosa · Phase 2/Phase 3
- Anterior Cruciate Ligament Injuries · Phase 3
- Antisocial Personality Disorder · Phase 4
- Anxiety · Phase 2
- Arthralgia · Phase 3
- Arthroplasty, Replacement, Hip · Phase 3
- Atherosclerosis · Phase 4
- Athletic Performance · Phase 2
- Back Pain · Phase 2
- Bariatric Surgery · Phase 4
- Bone Diseases, Metabolic · Phase 2
- Brain Injuries · Phase 4
- BRCA1 Protein · Phase 2
- Breast Density · Phase 1
- Breast Neoplasms · Phase 3
- Bulbo-Spinal Atrophy, X-Linked · Phase 2
- Cachexia · Phase 2
- Caloric Restriction · Phase 4
- Cancer Survivors · Phase 3
- Carcinoma, Intraductal, Noninfiltrating · Phase 2
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Squamous Cell · Phase 1
- Cardiovascular Diseases · Phase 4
- Central Nervous System Diseases · Phase 2
- Cerebral Arterial Diseases · Early Phase 1
- Chronic Pain · Phase 1/Phase 2
- Cognitive Dysfunction · Phase 3
- Contraception · Phase 2
- Contraceptive Agents, Male · Phase 2
- Coronary Artery Disease · Phase 3
- Coronary Disease · Phase 2
- COVID-19 · Phase 4
- Critical Illness · Phase 2
- Deficiency Diseases · Phase 3
- Depression · Phase 2
- Dermatology · Phase 1
- Diabetes Mellitus · Phase 4
- Diabetes Mellitus, Type 2 · Phase 4
- Disability Evaluation · Phase 2
- Disorder of Sex Development, 46,XY · Phase 3
- Dyspareunia · Phase 1/Phase 2
- Dysthymic Disorder · Phase 4
- Ejaculation · Phase 2
- Endocrine Glands · Phase 4
- Endocrine System Diseases · Phase 2
- Enteral Nutrition · Phase 3
- Erectile Dysfunction · Phase 4
- Eunuchism · Phase 4
- Exercise · Phase 4
- Fatigue · Phase 2
- Fatigue Syndrome, Chronic · Phase 4
- Fatty Liver · Phase 4
- Feeding and Eating Disorders · Phase 2
- Female · Phase 2
- Fertilization in Vitro · Phase 3
- Frailty · Phase 4
- Gait Disorders, Neurologic · Phase 2
- Gender Dysphoria · Phase 4
- General Surgery · Phase 2/Phase 3
- Genital Diseases, Male · Phase 2
- Gonadal Disorders · Phase 2
- Growth and Development · Phase 2/Phase 3
- Growth Hormone · Phase 2
- Health Services for Transgender Persons · Early Phase 1
- Healthy Aging · Phase 2/Phase 3
- Healthy Volunteers · Phase 4
- Heart Failure · Phase 4
- Hip Fractures · Phase 3
- Hip Injuries · Phase 3
- HIV Infections · Phase 4
- HIV Wasting Syndrome · Phase 2
- Homologous Recombination · Phase 2
- Hormones · Phase 2
- Hot Flashes · Phase 3
- Hypopituitarism · Phase 4
- Infertility · Phase 3
- Infertility, Female · Phase 4
- Infertility, Male · Phase 2/Phase 3
- Insulin Resistance · Phase 2
- Kallmann Syndrome · Phase 4
- Kidney Failure, Chronic · Phase 3
- Klinefelter Syndrome · Phase 4
- Knee Injuries · Phase 2/Phase 3
- Leydig Cells · Phase 2/Phase 3
- Liver Cirrhosis · Phase 2
- Long QT Syndrome · Phase 4
- Lower Urinary Tract Symptoms · Phase 4
- Lung Diseases · Phase 3
- Major Depressive Disorder · Phase 4
- Male · Phase 3
- Malnutrition · Phase 3
- Meibomian Gland Dysfunction · Phase 2
- Men · Phase 2
- Menopause · Phase 3
- Metabolic Diseases · Phase 1/Phase 2
- Metabolic Syndrome · Phase 4
- Metabolism · Phase 2
- Mobility Limitation · Phase 4
- Multiple Sclerosis · Phase 4
- Multiple Sclerosis, Relapsing-Remitting · Phase 2
- Muscle Hypotonia · Phase 4
- Muscles · Phase 2
- Muscle Weakness · Phase 4
- Muscular Atrophy · Phase 4
- Muscular Atrophy, Spinal · Phase 2
- Muscular Diseases · Phase 4
- Muscular Dystrophy, Facioscapulohumeral · Phase 1
- Musculoskeletal Diseases · Phase 4
- Mutation · Phase 2
- Myocardial Infarction · Phase 2/Phase 3
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 3
- Nervous System Diseases · Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 2
- Obesity · Phase 4
- Opioid-Related Disorders · Phase 1/Phase 2
- Osteoarthritis · Phase 3
- Osteoporosis · Phase 4
- Ovarian Diseases · Phase 3
- Pain · Phase 4
- Penile Induration · Phase 1
- Penis · Phase 4
- Periodontitis · Phase 4
- Peripheral Vascular Diseases · Phase 4
- Pharmacokinetics · Phase 1
- Placebos · Phase 4
- Polyneuropathies · Phase 2/Phase 3
- Postmenopause · Phase 2
- Priapism · Early Phase 1
- Primary Ovarian Insufficiency · Phase 1/Phase 2
- Prostate · Phase 2
- Prostatic Hyperplasia · Phase 4
- Prostatic Neoplasms · Phase 4
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Pulmonary Disease, Chronic Obstructive · Phase 2/Phase 3
- Renal Insufficiency, Chronic · Phase 2
- Reproductive Medicine · Phase 4
- Rotator Cuff Injuries · Phase 2/Phase 3
- Sarcopenia · Phase 4
- Sexual Behavior · Phase 2
- Sexual Dysfunction, Physiological · Phase 4
- Sexual Dysfunctions, Psychological · Phase 4
- Sexual Health · Phase 3
- Sleep · Phase 4
- Spinal Cord Diseases · Phase 2
- Spinal Cord Injuries · Phase 2/Phase 3
- Substance Abuse, Oral · Phase 4
- Testicular Neoplasms · Phase 2/Phase 3
- Testosterone · Phase 4
- Transgender Persons · Early Phase 1
- Transsexualism · Phase 4
- Trauma, Nervous System · Phase 2
- Turner Syndrome · Phase 3
- Urinary Incontinence · Phase 3
- Urinary Incontinence, Stress · Phase 2
- Urination Disorders · Phase 1
- Vaginal Diseases · Early Phase 1
- Vaginitis · Phase 1/Phase 2
- Ventilators, Mechanical · Phase 4
- Weaning · Phase 4
- Women's Health · Phase 2
- Wounds and Injuries · Phase 4
Mechanism of action
- Androgen ReceptorAGONIST
AR agonist
Combination products
depo-testadiol
with estradiol
Also known as ditate-ds, testosterone cypionate-estradiol cypionate
Approval history
- approvedPriority reviewDec 24, 1953
Chemistry & pharmacology
SMILES
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O- Mol. weight
- 288.4244 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaTestosterone propionate ↗
- NCATS3XMK78S47O ↗
- ChEMBLCHEMBL1201101 ↗
- ChEMBLCHEMBL1200335 ↗
- ChEMBLCHEMBL386630 ↗
- WikipediaTestosterone undecanoate ↗
- WikipediaTestosterone enanthate ↗
- ChEMBLCHEMBL1170 ↗
- ChEMBLCHEMBL2107067 ↗
Also known as
- 17beta-hydroxy-4-androsten-3-one
- 17beta-hydroxy-4-androsten-3-one
- 17beta-testosterone
- 4-androsten-17β-ol-3-one
- 4-androsten-17β-ol-3-one
- abt-slv176
- abt-slv361
- andriol
- andriol
- andriol
- andro-cyp
- andro-cyp
- androderm
- androderm
- androderm
- androgel
- androgel
- androgel 1%
- androgel 1%
- andronate
- andropatch
- andropatch
- andropository
- androst-4-en-3-one, 17-((1-oxoundecyl)oxy)-, (17-beta)
- androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17-beta)-
- ard-0403
- axiron
- axiron
- btg brand of testosterone enanthate
- delatestryl
- delatestryl
- delatestryl
- delatestryl
- depandro
- depandro
- deposteron
- depostomead
- depotest
- depotest
- depo-testadiol
- depo-testadiol
- depo-testosterone
- depo-testosterone
- depo-testosterone
- depo-testosterone cypionate
- duratest
- durathate
- eifelfango brand of testosterone enanthate
- fortesta
- fortesta
- intrinsa
- intrinsa
- jenapharm brand of testosterone enanthate
- mertestate
- mertestate
- nebido
- nebido
- nebido
- org-538
- org-538
- organon brand of testosterone undecanoate
- pantestone
- pasadena brand of testosterone enanthate
- primoteston depot
- primoteston depot
- primoteston depot
- restandol
- restandol
- restandol
- restandol testocap
- roberts brand of testosterone enanthate
- rotexmedica brand of testosterone enanthate
- rugby brand of testosterone enanthate
- schering brand of testosterone enanthate
- striant
- striant
- striant sr
- testa-c
- testex
- testex
- testex elmu
- testim
- testim
- testim
- testim 1%
- testoderm
- testoderm
- testoderm tts
- testoderm tts
- testogel
- testogel
- testopatch
- testopel
- testopel
- testoral
- testoral
- testosteron
- testosteron
- testosterona
- testosterona
- testosteron-depot eifelfango
- testosteron-depot jenapharm
- testosteron depot-rotexmedica
- testosterone
- testosterone
- testosterone
- testosterone
- testosterone
- testosterone
- testosterone
- testosterone
- testosterone
- testosterone
- testosterone
- testosterone
- testosterone
- testostérone
- testostérone
- testosterone 17 beta-cyclopentanepropionate
- testosterone 17 beta-cyclopentylpropionate
- testosterone 17 beta-cypionate
- testosterone cyclopentylpropionate
- testosterone cyclopentylpropionate
- testosterone cyclopentylpropionate
- testosterone cyclopentylpropionate
- testosterone cypionate
- testosterone cypionate
- testosterone cypionate
- testosterone cypionate
- testosterone cypionate
- testosterone cypionate
- testosterone cypionate
- testosterone cypionate
- testosterone enantate
- testosterone enantate
- testosterone enantate
- testosterone enantate
- testosterone enanthate
- testosterone enanthate
- testosterone enanthate
- testosterone enanthate
- testosterone enanthate
- testosterone enanthate
- testosterone enanthate
- testosterone heptanoate
- testosterone heptanoate
- testosterone heptanoate
- testosterone heptylate
- testosterone heptylate
- testosterone oenanthate
- testosterone propionate
- testosterone propionate
- testosterone propionate
- testosterone propionate
- testosterone propionate
- testosterone propionate
- testosterone propionate
- testosterone propionate
- testosterone undecanoate
- testosterone undecanoate
- testosterone undecanoate
- testosterone undecanoate
- testosterone undecanoate
- testosterone undecanoate
- testosterone undecanoate
- testosterone undecanoate
- testosterone undeconate
- testosterone undeconate
- testosterone undecylate
- testosterone undecylate
- testosteronum
- testosteronum
- testoviron
- testoviron
- testrin p.a.
- theramed brand of testosterone enanthate
- theramex
- tostran
- tsx-002
- undestor
- undestor
- undestor
- virormone
- virormone
- virormone
- virormone
- virormone
- virormone
- virosterone
- virosterone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07212712 | N/A | Mar 1, 2026 | University of British Columbia |
| NCT07278362 | Phase 4 | Feb 28, 2026 | University of Miami |
| NCT07260825 | Phase 2/Phase 3 (Phase 3) | Dec 31, 2025 | TriHealth |
| NCT07142551 | Phase 2 | Dec 30, 2025 | Bayer, Johns Hopkins University |
| NCT07092527 | Phase 4 | Dec 1, 2025 | National Institutes of Health (NIH), University of California, San Diego |
| NCT07254429 | Phase 2 | Oct 2, 2025 | University of Copenhagen |
| NCT06922318 | Phase 2 | Aug 19, 2025 | Johns Hopkins University, National Cancer Institute (NCI), Zenith Epigenetics |
| NCT07028255 | N/A | Jul 1, 2025 | Qualia Life Sciences |
| NCT07287800 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2025 | University of California, Los Angeles |
| NCT06720597 | N/A | Jan 31, 2025 | University of California, Irvine |
| NCT06689085 | Phase 3 | Jan 31, 2025 | Halozyme Therapeutics |
| NCT06733350 | Phase 4 | Jan 1, 2025 | State University of New York, Buffalo |
| NCT06305598 | Phase 1 | Dec 15, 2024 | State University of New York, Buffalo |
| NCT06450405 | Phase 4 | Nov 15, 2024 | National Institutes of Health (NIH), University of California, San Diego |
| NCT06592144 | Phase 4 | Sep 9, 2024 | University of Sao Paulo |
| NCT06188767 | N/A | Sep 1, 2024 | University of Copenhagen |
| NCT06294990 | N/A | Aug 15, 2024 | University of Copenhagen |
| NCT06594926 | Phase 2 | Aug 14, 2024 | Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, University of New South Wales |
| NCT06455969 | Phase 4 | Jul 15, 2024 | United States Army, University of Pittsburgh |
| NCT06351501 | Phase 3 | Jun 6, 2024 | Assistance Publique - Hôpitaux de Paris |
Organizations
Research & Development (332)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institutes of Health (NIH) | Government | 30 | 5 | 5 | 1999 |
| University of Washington | Academic/Hospital | 26 | 24 | 5 | 2002 |
| Harvard University | Academic/Hospital | 25 | 18 | 5 | 1998 |
| Solvay | For profit | 21 | 4 | 5 | 2002 |
| Department of Veteran Affairs | Government | 20 | 14 | 5 | 1999 |
| Johns Hopkins University | Academic/Hospital | 16 | 15 | 5 | 2008 |
| Bayer | For profit | 14 | 4 | 3 | 2003 |
| Clarus Therapeutics, Inc. | For profit | 14 | 11 | 4 | 2007 |
| National Institute on Aging (NIA) | Government | 12 | 4 | 4 | 1999 |
| Acerus Pharmaceuticals Corporation | For profit | 11 | 8 | 4 | 2009 |
| National Cancer Institute (NCI) | Government | 10 | 2 | 4 | 2000 |
| University of California, Los Angeles | Academic/Hospital | 10 | 4 | 4 | 2002 |
| Merck | For profit | 9 | 7 | 2 | 2001 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 9 | 4 | 5 | 1998 |
| University of Colorado, Denver | Academic/Hospital | 9 | 7 | 5 | 2005 |
| Warner Chilcott | For profit | 9 | 9 | 3 | 2002 |
| Abbott | For profit | 8 | 4 | 3 | 2007 |
| Boston University | Academic/Hospital | 8 | 4 | 4 | 2002 |
| Eli Lilly | For profit | 8 | 8 | 4 | 2007 |
| Endo Pharmaceuticals | For profit | 8 | 4 | 3 | 2006 |
Marketing (85)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AYTU BioScience | For profit | NDA2 | May 28, 2014 |
| AbbVie | For profit | NDA2 | Feb 28, 2000 |
| Acerus Pharmaceuticals Corporation | For profit | MKTG | May 28, 2014 |
| Actavis | For profit | MKTG | Jan 27, 2006 |
| Alembic | For profit | MKTG | Mar 3, 2021 |
| Alembic | For profit | SYN | Mar 3, 2021 |
| Allergan | For profit | NDA2 | Sep 29, 1995 |
| Allergan | For profit | MKTG | Sep 29, 1995 |
| Allergan PLC (2015) | For profit | MKTG | Aug 5, 2015 |
| Alza | For profit | NDA2 | Oct 12, 1993 |
| Amneal Pharmaceuticals | For profit | MKTG | Apr 10, 2019 |
| Amneal Pharmaceuticals | For profit | SYN | Apr 10, 2019 |
| Ani Pharmaceuticals | For profit | NDA2 | Feb 14, 2012 |
| Ani Pharmaceuticals | For profit | SYN | Feb 14, 2012 |
| Antares Pharma Inc. | For profit | NDA2 | Sep 28, 2018 |
| Apotex | For profit | MKTG | Nov 25, 2020 |
| Athenex, Inc. | For profit | MKTG | — |
| Auxillium | For profit | NDA2 | Oct 31, 2002 |
| Auxillium | For profit | MKTG | Jul 13, 1972 |
| Azurity | For profit | MKTG | Jun 2, 2022 |
| Bausch Health Companies | For profit | NDA2 | May 28, 2014 |
| Belmar Pharmacy | For profit | MKTG | Dec 3, 1973 |
| Besins Healthcare | For profit | MKTG | Feb 28, 2000 |
| Besins Healthcare | For profit | NDA2 | Feb 28, 2000 |
| Bristol-Myers Squibb | For profit | NDA2 | Dec 29, 2010 |
| Cipla | For profit | MKTG | Jan 29, 2018 |
| Clarus Therapeutics, Inc. | For profit | NDA2 | Mar 27, 2019 |
| Clarus Therapeutics, Inc. | For profit | MKTG | Mar 27, 2019 |
| Daiichi Sankyo | For profit | MKTG | Jun 16, 2017 |
| Dash Pharms | For profit | MKTG | Jan 11, 2021 |
| Dr. Reddy's Laboratories | For profit | SYN | Jul 7, 1983 |
| Dr. Reddy's Laboratories | For profit | MKTG | Apr 10, 2019 |
| Eli Lilly | For profit | NDA2 | Nov 23, 2010 |
| Eli Lilly | For profit | MKTG | — |
| Elkins Sinn | For profit | MKTG | — |
| Encube Ethicals Pvt. Ltd. | For profit | MKTG | Nov 9, 2021 |
| Endo Pharmaceuticals | For profit | NDA2 | Dec 24, 1953 |
| Endo Pharmaceuticals | For profit | NDA | Dec 24, 1953 |
| Endo Pharmaceuticals | For profit | MKTG | Mar 5, 2014 |
| Endo Pharmaceuticals | For profit | SYN | Jul 13, 1972 |
| Eugia Pharma | For profit | MKTG | Oct 20, 2023 |
| Exeltis | For profit | MKTG | Apr 16, 2020 |
| Hikma | For profit | MKTG | May 1, 2012 |
| Hikma | For profit | MKTG | Jul 15, 2010 |
| Hikma | For profit | MKTG | Jul 15, 2010 |
| Lipocine Inc. | For profit | MKTG | Dec 8, 2020 |
| Lupin | For profit | SYN | Apr 13, 2018 |
| Lupin | For profit | MKTG | Oct 23, 2017 |
| Lupin | For profit | SYN | Apr 10, 2019 |
| Lutipold | For profit | MKTG | Jun 16, 2017 |
| MARIUS PHARMS LLC | For profit | MKTG | Jul 27, 2022 |
| MARIUS PHARMS LLC | For profit | NDA2 | Jul 27, 2022 |
| Mylan | For profit | MKTG | Dec 11, 2006 |
| Nexus Pharmaceuticals | For profit | MKTG | Jun 14, 2006 |
| Nexus Pharmaceuticals | For profit | SYN | Jun 14, 2006 |
| Novartis | For profit | MKTG | Aug 10, 2006 |
| Padagis Us | For profit | MKTG | Aug 4, 2015 |
| Padagis Us | For profit | MKTG | Jan 31, 2005 |
| Paddock Laboratories | For profit | MKTG | Jan 31, 2005 |
| Paddock Laboratories | For profit | SYN | Dec 9, 2016 |
| Par Pharmaceuticals | For profit | MKTG | May 23, 2007 |
| Perrigo | For profit | NDA2 | Jan 31, 2013 |
| Perrigo | For profit | MKTG | Jul 12, 2017 |
| Pfizer | For profit | MKTG | Jul 25, 1979 |
| Pharmacia & Upjohn | For profit | MKTG | Jul 25, 1979 |
| Pharmacia & Upjohn | For profit | NDA2 | Jun 13, 1980 |
| Rising Pharmaceuticals | For profit | MKTG | Dec 11, 2006 |
| Rising Pharmaceuticals | For profit | SYN | Dec 11, 2006 |
| Sandoz | For profit | MKTG | Aug 10, 2006 |
| Sandoz | For profit | SYN | Aug 10, 2006 |
| Sankyo | For profit | MKTG | Jun 16, 2017 |
| Savage Labs | For profit | MKTG | Jun 29, 1982 |
| Slayback Pharma Llc | For profit | MKTG | Jun 2, 2022 |
| Slayback Pharma Llc | For profit | NDA2 | Jun 2, 2022 |
| Strides Pharma Science | For profit | MKTG | May 23, 2007 |
| Sun Pharmaceuticals | For profit | MKTG | Jun 3, 2013 |
| TWi Biotechnology, Inc. | For profit | MKTG | Sep 23, 2019 |
| Tolmar Inc. | For profit | MKTG | Mar 27, 2019 |
| Tolmar Inc. | For profit | NDA2 | Mar 27, 2019 |
| Upsher-Smith Laboratories | For profit | NDA2 | Jun 4, 2014 |
| Verity Pharmaceuticals | For profit | MKTG | Mar 28, 2022 |
| Watson Pharmaceuticals | For profit | MKTG | Jun 23, 1978 |
| Watson Pharmaceuticals | For profit | SYN | Dec 10, 1980 |
| West-Ward Pharmaceutical | For profit | MKTG | Jul 15, 2010 |
| Wilshire Pharmaceuticals | For profit | MKTG | Apr 24, 2019 |